Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Alvotech - Ordinary Shares
(NQ:
ALVO
)
13.22
+0.33 (+2.56%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,686,575
Open
13.05
Bid (Size)
12.50 (1)
Ask (Size)
13.53 (1)
Prev. Close
12.89
Today's Range
12.75 - 14.00
52wk Range
6.700 - 18.00
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Fifth Third Bancorp Reports Upbeat Earnings, Joins Metropolitan Bank Holding, Paramount Global And Other Big Stocks Moving Higher On Friday
April 19, 2024
Via
Benzinga
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
April 19, 2024
From
Alvotech
Via
GlobeNewswire
Performance
YTD
+16.37%
+16.37%
1 Month
-13.20%
-13.20%
3 Month
-6.51%
-6.51%
6 Month
+52.30%
+52.30%
1 Year
+32.86%
+32.86%
More News
Read More
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
April 16, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
ALVO Stock Earnings: Alvotech Reported Results for Q4 2023
March 20, 2024
Via
InvestorPlace
Alvotech's Earnings: A Preview
March 19, 2024
Via
Benzinga
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
April 16, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
April 03, 2024
From
Alvotech
Via
GlobeNewswire
Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday
March 25, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Alvotech Announces Increase in Number of Own Shares
March 22, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
March 20, 2024
From
Alvotech
Via
GlobeNewswire
Earnings Scheduled For March 20, 2024
March 20, 2024
Via
Benzinga
Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET
March 05, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech Appoints Interim Chief Quality Officer
February 29, 2024
From
Alvotech
Via
GlobeNewswire
TEVA Stock Pops 4% as Teva Receives FDA Approval
February 26, 2024
Via
InvestorPlace
Exposures
Product Safety
Why Is Generic Drugs Player Teva Pharma Stock Trading Higher Today?
February 26, 2024
Via
Benzinga
Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
February 26, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
February 23, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
February 23, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)
February 15, 2024
From
Alvotech
Via
GlobeNewswire
American Airlines To Rally Around 32%? Here Are 10 Top Analyst Forecasts For Monday
January 29, 2024
Via
Benzinga
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
January 29, 2024
From
Alvotech
Via
GlobeNewswire
3 mid-caps under $20 that Wall Street loves
January 23, 2024
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Exposures
Artificial Intelligence
Interest Rates
12 Health Care Stocks Moving In Friday's Intraday Session
January 19, 2024
Via
Benzinga
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04
January 19, 2024
From
Alvotech
Via
GlobeNewswire
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
January 10, 2024
From
Alvotech
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.